MediPharm Labs reported $45.1 million in revenue for 2025, up 8% from 2024, with international medical cannabis revenue surging 43% to $25.2 million, making up over half of total sales. The company ended the year with a strong balance sheet, holding $10.8 million in cash and virtually no debt, supported by cost controls and asset monetization. Looking ahead, MediPharm plans to expand its product portfolio and geographic reach, targeting markets like Brazil, France, and New Zealand while maintaining disciplined growth. This performance highlights MediPharm's focus on responsible growth and long-term value creation in the regulated medical cannabis sector.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
AmpliTech Group marked its fifth anniversary as a public company by ringing the Nasdaq opening bell and announcing record revenue of $25.2 million in fiscal 2025, a 165% increase year-over-year. The company, a US-based leader in RF and microwave sign...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
